How UCL Ventures’ neuroscience spinouts are making breakthroughs to change lives

As UCL’s renowned Neuroscience Symposium kicks off, we uncover our spinouts’ work from tackling motor neurone disease to redefining AI.

Neuroscience stock image

Trace Neuroscience: genomic medicine for motor neurone disease


Launched in late 2024, Trace Neuroscience is backed by a $101m Series A round. Trace is developing a genomic therapy for motor neurone disease (MND), also known as ALS, targeting a key protein called UNC13A.
Find out more.

Stanhope AI: neuroscience-inspired Artificial Intelligence


Stanhope AI is pioneering ‘agentic AI’ based on the neuroscience principle of Active Inference and has raised £2.3m to develop algorithms that mimic how the human brain predicts and adapts to the world.
For more information.

EpilepsyGTx: gene therapy meets epilepsy


EpilepsyGTx is developing a portfolio of gene therapies based on research from the UCL Queen Square Institute of Neurology.
Read more.

ReadClear: the app helping brain-related visual impairment


ReadClear is an assistive reading aid for people with brain-related visual impairment, developed by Dr Aida Suárez-González.
Discover more.